EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epimedium koreanum Nakai attenuates glucocorticoid-induced osteoporosis by suppressing ferroptosis via the KEAP1/NRF2/SLC7A11/GPX4 axis: comparative pharmacodynamic evaluation of four epimedium species and proteomic and metabolomic analyses of epk

Tian-Yang Xu, Pan Li, Zi-Meng Qi, Jing-Zhen Wu, Shi-Chang Li, Jin-Ling Liang, Jia Liu, Peng Yu

Frontiers in Pharmacology · 29.10.2026 · 17

DOI: 10.3389/fphar.2026.1948777 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.10.2026. Verfasst von Tian-Yang Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The pharmacodynamics and underlying mechanisms of Epimedium (Yingyanghuo), a traditional Chinese medicine, were investigated in the context of glucocorticoid-induced osteoporosis (GIOP) management, with particular emphasis on ferroptosis inhibition.

Methods

A rat model of GIOP was developed through dexamethasone (DEX) administration. Animals received extracts of the four Epimedium species; Epimedium koreanum Nakai (Epk) was selected for subsequent investigation owing to its superior preliminary efficacy. Evaluations encompassed bone microstructure, osteoclast activity, serum biomarkers of bone metabolism, oxidative stress, lipid peroxidation and iron accumulation indicators (4-HNE and Fe 2+ ), and ferroptosis-associated proteins (KEAP1/NRF2/SLC7A11/GPX4 pathway). Integration of proteomics and metabolomics facilitated the identification of key pathways, followed by experimental validation of ferroptosis modulation.

Results

Epk treatment mitigated DEX-induced bone loss, improved bone microarchitecture, and suppressed osteoclast activity. Multi-omics approaches uncovered reversal of 368 proteins and 127 metabolites in GIOP rats following Epk administration, with enrichment observed in ferroptosis, glutathione metabolism, and oxidative phosphorylation. Treatment with Epk further reduced the elevated femoral 4-HNE and Fe 2+ levels in GIOP rats. Epk treatment elevated NRF2, HO-1, SLC7A11, and GPX4 and reduced KEAP1 and P53 in bone tissue, consistent with suppression of ferroptosis-related signaling.

Conclusion

Epimedium, with Epk as the prominent representative, confers substantial protection against GIOP, with effects associated with modulation of the KEAP1/NRF2/SLC7A11/GPX4 pathway and suppression of ferroptosis-related markers in bone tissue, thereby providing a basis for further investigation of its clinical potential in GIOP management.

Schlagwörter

Stichwörter der Autor:innen

KEAP1/NRF2/SLC7A11/GPX4 axisepimediumferroptosisglucocorticoid‐induced osteoporosismetabolomicsproteomics

Autor:innen und Institutionen

  • Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, China.
  • School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China.
  • Institute of Medicine and Drug Research, Qiqihar Medical University, Qiqihar, China.
  • Scientific Research Department, Changchun University of Chinese Medicine, Changchun, China.

Zitieren

APA

Xu, T. Y., Li, P., Qi, Z. M., Wu, J. Z., Li, S. C., Liang, J. L., Liu, J., & Yu, P. (2026). Epimedium koreanum Nakai attenuates glucocorticoid-induced osteoporosis by suppressing ferroptosis via the KEAP1/NRF2/SLC7A11/GPX4 axis: comparative pharmacodynamic evaluation of four epimedium species and proteomic and metabolomic analyses of epk. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1948777

Vancouver

Xu TY, Li P, Qi ZM, Wu JZ, Li SC, Liang JL, et al. Epimedium koreanum Nakai attenuates glucocorticoid-induced osteoporosis by suppressing ferroptosis via the KEAP1/NRF2/SLC7A11/GPX4 axis: comparative pharmacodynamic evaluation of four epimedium species and proteomic and metabolomic analyses of epk. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1948777

BibTeX
@article{Xu2026,
  author = {Xu, Tian-Yang and Li, Pan and Qi, Zi-Meng and Wu, Jing-Zhen and Li, Shi-Chang and Liang, Jin-Ling and Liu, Jia and Yu, Peng},
  title = {Epimedium koreanum Nakai attenuates glucocorticoid-induced osteoporosis by suppressing ferroptosis via the KEAP1/NRF2/SLC7A11/GPX4 axis: comparative pharmacodynamic evaluation of four epimedium species and proteomic and metabolomic analyses of epk},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1948777}
}
Kostenlos starten →